Jonathan E. Lim

CIK: 0001283290

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)8 (72.7%)

Compensation grants

Other (G, F, J, C, D, …)3 (27.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

BOLD

Boundless Bio, Inc.

Director

MAZE

Maze Therapeutics, Inc.

Director

ERAS

Erasca, Inc.

DirectorOfficer10% Owner

Discretionary Trading P&L

Holdings

Transaction History (11 total)

BOLD
Boundless Bio, Inc.
Jun 15, 2026
Award(A)
Stock Option (right to buy)
Direct
48K shares-
MAZE
Maze Therapeutics, Inc.
Jun 8, 2026
Award(A)
Stock Option (Right to Buy)
Direct
18K shares-
ERAS
Erasca, Inc.
Jan 29, 2026
Award(A)
Stock option (right to buy)
Direct
2M shares-
MAZE
Maze Therapeutics, Inc.
Sep 22, 2025
Award(A)
Stock Option (Right to Buy)
Direct
18K shares-
BOLD
Boundless Bio, Inc.
Jun 23, 2025
Award(A)
Stock Option (right to buy)
Direct
24K shares-
ERAS
Erasca, Inc.
Feb 3, 2025
Award(A)
Stock option (right to buy)
Direct
2.5M shares-
MAZE
Maze Therapeutics, Inc.
Feb 3, 2025
Conversion(C)
Indirect
270.2K shares-
MAZE
Maze Therapeutics, Inc.
Feb 3, 2025
Conversion(C)
Indirect
37.7K shares-
MAZE
Maze Therapeutics, Inc.
Dec 9, 2024
Award(A)
Stock Option (Right to Buy)
Direct
5.7K shares-
MAZE
Maze Therapeutics, Inc.
Dec 9, 2024
Disposition(D)
Stock Option (Right to Buy)
Direct
5.7K shares-
MAZE
Maze Therapeutics, Inc.
Dec 9, 2024
Award(A)
Stock Option (Right to Buy)
Direct
9.1K shares-

		Type	Shares	Price		Ownership
Jun 15, 2026	BOLD Boundless Bio, Inc.	Award(A) Stock Option (right to buy)	48,000	-	-	Direct
Jun 8, 2026	MAZE Maze Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	18,000	-	-	Direct
Jan 29, 2026	ERAS Erasca, Inc.	Award(A) Stock option (right to buy)	2,000,000	-	-	Direct
Sep 22, 2025	MAZE Maze Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	18,000	-	-	Direct
Jun 23, 2025	BOLD Boundless Bio, Inc.	Award(A) Stock Option (right to buy)	24,000	-	-	Direct
Feb 3, 2025	ERAS Erasca, Inc.	Award(A) Stock option (right to buy)	2,500,000	-	-	Direct
Feb 3, 2025	MAZE Maze Therapeutics, Inc.	Conversion(C)	270,232	-	-	Indirect
Feb 3, 2025	MAZE Maze Therapeutics, Inc.	Conversion(C)	37,724	-	-	Indirect
Dec 9, 2024	MAZE Maze Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	5,704	-	-	Direct
Dec 9, 2024	MAZE Maze Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	5,704	-	-	Direct
Dec 9, 2024	MAZE Maze Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	9,086	-	-	Direct

1-11 of 11 transactions

About Lim Jonathan E

Lim Jonathan E (SEC CIK 0001283290) files insider reports with the SEC as Director of Boundless Bio, Inc. (BOLD), Director of Maze Therapeutics, Inc. (MAZE) and Chairman & CEO of Erasca, Inc. (ERAS).

Signal8 holds 8 ownership filings by Lim Jonathan E (1 Form 3, 7 Form 4), filed between Jan 30, 2025 and Jun 15, 2026. Those filings report 11 transactions, from Dec 9, 2024 to Jun 15, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Lim Jonathan E's filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by Lim Jonathan E

Jun 15, 2026: Grant or award of BOLD derivative securities (Form 4, code A).
Jun 8, 2026: Grant or award of MAZE derivative securities (Form 4, code A).
Jan 29, 2026: Grant or award of ERAS derivative securities (Form 4, code A).
Sep 22, 2025: Grant or award of MAZE derivative securities (Form 4, code A).
Jun 23, 2025: Grant or award of BOLD derivative securities (Form 4, code A).

Other insiders filing for Boundless Bio, Inc. (BOLD)

TANG KEVIN, 10% Owner
CRANDELL KEITH, 10% Owner
ARCH Venture Fund IX, L.P., 10% Owner
Whiting Nancy, Director
Christensen James, Director
Lew Jennifer, Director

How to read Form 4 transaction codes